Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis

Table 6

Subgroup analysis of ET-1 based on dosage form, drug, sample size, treatment duration, sex ratio, average age, location, and year.

Items	Subgroup	n	SMD (95% CI)	I ^2 (%)	z
Dosage form	Pill	3	−1.70 (−2.16, −1.24)	52.0	−7.198	<0.001
	Dropping pill	1	−2.53 (−3.05, −2.02)	—	−9.670	<0.001
	Capsule	7	−1.68 (−2.13, −1.23)	79.6	−7.309	<0.001
Drug	TXLC	3	−1.73 (−2.67, −0.80)	84.7	−3.632	<0.001
	SBP	3	−1.70 (−2.16, −1.24)	52.0	−7.198	<0.001
	YXSC	2	−1.39 (−2.42, −0.36)	91.4	−2.636	0.008
Sample size	≥80	4	−1.83 (−2.53–1.13)	88.6	−5.109	<0.001
	<80	7	−1.73 (−2.11, −1.36)	65.5	−8.986	<0.001
Treatment duration	≥6 months	4	−1.63 (−2.20, −1.07)	80.5	−5.681	<0.001
	<6 months	7	−1.85 (−2.30, −1.41)	76.7	−8.143	<0.001
Sex ratio	F/M ≥ 100%	8	−1.85 (−2.20, −1.48)	73.0	−9.822	<0.001
	F/M < 100%	3	−1.56 (−2.34, −0.79)	84.0	−3.946	<0.001
Average age	>60	4	−1.88 (−2.37, −1.39)	74.9	−7.508	<0.001
	<60	7	−1.70 (−2.18, −1.22)	79.8	−6.936	<0.001
Location	North	8	−1.99 (−2.28, −1.70)	56.1	−13.529	<0.001
	South	3	−1.16 (−1.76, −0.56)	72.2	−3.774	<0.001
Year	2016	2	−1.82 (−2.22, −1.41)	0.0	−8.763	<0.001
	2018	2	−2.27 (−2.81, −1.74)	37.0	−8.259	<0.001